Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of M7583 in Healthy Volunteers
NCT03297983Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TL-895 in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at Day 1, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 1 and 1 more. Started Oct 2017; status: completed.
02
Drugs
TL-895
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03297983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297983.